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INTRODUCTION
ACCESS TO STERILE SYRINGES is critical to lower the
risk of transmission of HIV and other blood-borne pathogens
among injection drug users (IDUs). Several strategies to in-
crease access to sterile syringes among injection drug users
have been tried, including needle exchange proqrams (NEPs),
which have been replicated throughout the world. In the United
States, health officials have recommended that state and local
laws be modified to allow the legal purchase and possession of
syringes.2 This has been done successfully in Connecticut, Min-
t Brown University
tt Miriam Hospital
ttt University of North Carolina, Chapel Hill
tttt Temple University School of Law
1 See Donald C. Des Jarlais & Samuel R. Friedman, Research, in DwIENSIONS
OF HIV PR ENmON: NEEDLE EXCHANGE 63, 64 (Jeff Stryker & Mark D. Smith eds.,
1993) (testing the possible positive and negative effects of needle exchange programs
as a means of preventing the further spread of AIDS among IDUs).
2 Organizations supporting syringe access include: the American Medical
Association (AMA), the American Pharmaceutical Association (APhA), the Associa-
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nesota, and Maine.3 An additional strategy is to have physicians
prescribe syringes to injection drug users to decrease the risk of
transmission of HIV and other blood-borne pathogens.4 To the
best of our knowledge, only a few physicians, in rare situations,
have tried this method of increasing access to sterile syringes.
This strategy has the added advantage of bringing injection drug
users into medical care, developing a physician-patient relation-
ship, and increasing the potential for the provision of medical
care to a population at high risk for disease. It can also facilitate
access to social services, mental health services, and substance
abuse treatment. This article will describe the genesis of physi-
cian syringe prescription in Rhode Island and some of the les-
sons learned to date.
BACKGROUND
Access to sterile syringes varies tremendously by state and
is controlled by laws and regulations that are enforced, to vary-
ing degrees, in different regions.5 Rhode Island has had, per-
haps, the strictest syringe control laws in the United States. Un-
til recently, it was a felony offense to possess even a single sy-
ringe, punishable by up to five years in prison. This law was
vigorously enforced, costing the state over $1,000,000 per year
tion of State and Territorial Health Officials (ASTHO), and the National Alliance of
State and Territorial AIDS Directors (NASTAD).
3 see CoNN. GEN. STAT. ANN. § 21a-65 (West Supp. 2000) (permitting legal
possession of ten or fewer syringes); ME. REv. STAT. ANN. tit. 17-A, § 1111 (West
Supp. 1999) (defining "illegal possession" to include persons who intentionally or
knowingly furnish or possess II or more syringes) and ME. REV. STAT. ANN. tit. 22,
§ 2383-B(2)(F) (West Supp. 1999) (exempting syringe exchange program (SEP)
operators from prosecution); MIN. STAT. ANN. § 151.40(2) (West 1998) (permitting
registered or licensed pharmacists to legally sell unused hypodermic needles and
syringes in quantities of 10 or less); see also Linda A. Valleroy et al., Impact of In-
creased Legal Access to Needles and Syringes on Communi., Pharmacies' Needle
and Syringe Sales - Connecticut, 1992-1993, 10 J. ACQUiR. IMMUNE DEFIc. SYNDR. &
HuM. RmROVIROLOGY 73, 74 (1995) (permitting pharmacists and other health pro-
fessionals to sell up to 10 syringes and individuals without medical purposes to pos-
sess up to 10 syringes).
4 See Josiah D. Rich et al., Physician Syringe Prescription: A Pilot Interen-
lion to Prevent HIV and Hepatitis, (unpublished paper presented at the XIII Interna-
tional AIDS Conference, Durban, South Africa) (July 2000).
5 See Lawrence 0. Gostin, The Legal Environment Impeding Access to Sterile
Syringes and Needles: The Conflict Between Law Enforcement and Public Health, 18
J. AcQUIR. IMMUNE DBFIc. SYNDR. & HUM. RErROVIROLOGY S60, S6 1-S63 (Supp. I
1998) (examining the legal impediments to the sale and distribution of syringes in
various states).
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for incarceration costs alone.6 As a consequence, injection drug
users in Rhode Island have had the highest reported syringe re-
use rate (an average of 24 times per syringe) in the United
States which correlated with syringe sharing. In addition, street
prices for syringes are among the highest in the nation ($5 per
syringe).8
In fact, Rhode Island has had among the highest proportion
of AIDS cases related to injection drug use; it is one of four
states with over 50% of the AIDS cases associated with injec-
tion drug use.9 Injection drug use has been the leading risk fac-
tor associated with AIDS in Rhode Island since 1992. The high
proportion of AIDS cases related to injection drug use is a di-
rect consequence of syringe sharing due, in large part, to the
strict legal control of the purchase and possession of syringes in
Rhode Island.1°
LEGAL ACCESS TO SYRINGES
IN RHODE ISLAND
In response to a notification of the availability of funds
from the American Foundation for AIDS Research (amfAR) to
implement legal needle exchange programs, ACT-UP of Rhode
Island and other activists introduced a bill, successfully passed
by the Rhode Island legislature, allowing a legal pilot needle
exchange program in 1994. This pilot program, by design, was
6 See Josiah D. Rich et al., The Economic Cost of Strict Syringe Control, 81
MED. & HEALTH/R. 1. 207, 207 (1998) (noting that from 1994 to 1996, Rhode Island
spent $4,156,251 to incarcerate individuals violating syringe possession laws).
7 See Josiah D. Rich et al., Strict Syringe Laws in Rhode Island Are Associ-
ated With High Rates of Reusing Syringes and HIV Risks Among Injection Drug Us-
ers, 18 J. ACQUIR. IMMUNE DEFIc. SYNDR. & HuM. RETROVIROLOGY S140 (Supp. I
1998) (reporting that a syringe was reused on average 24 times).
s See Josiah D. Rich et al., High Street Prices of Syringes Correlate with
Strict Syringe Possession Laws, 26 AM. J. DRUG & ALCOHOL ABUsE 481, 483 (2000)
(finding that street syringe prices were higher in regions where syringe possession
laws were in place and higher still where laws were perceived as strictly enforced).
9 See Centers for Disease Control and Prevention, AIDS Associated with in-
jecting-Drug Use - United States, 1995, 45 MoRBIDrY & MORTALiTY WKLY. REP.
392 (1996) (indicating that IDU-associated AIDS accounted for more than 50% of
cases reported from Delaware, Connecticut, Maryland, and Rhode Island).
0 See Gostin, supra note 5, at S61-S63 (arguing that legal restrictions re-
garding access to sterile syringes presents tough obstacles to HIV/AIDS prevention).
See generally Lawrence 0. Gostin et al., Prevention of HIV/AIDS and Other Blood-
Borne Diseases Among Injection Drug Users: A National Suney on the Regulation of
Syringes and Needles, 227 JAMA 53 (1997).
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administered by the State Department of Health. By the time the
legislation was passed, the amfAR funding had been utilized in
other states. Even without this funding, the Rhode Island needle
exchange program began in 1995 and was run entirely by vol-
unteers on a "shoestring" budget in donated space. Enrollment
has steadily increased to over 1,700 participants. This is ap-
proximately 15% of the estimated 10,000 injection drug users in
the state. The few hours of operation and locations (initially
only four hours per week and in only a single location, currently
12 hours per week in two locations) have limited enrollment
and ongoing participation, especially among minorities. 12 How-
ever, the program continues to expand, and for the first time,
received substantial funding from the Rhode Island Department
of Health in 1999.13
Additional efforts to increase injection drug users' access
to sterile syringes to prevent the transmission of HIV and other
blood-borne diseases has led to an effort to change the laws
regulating syringe possession in Rhode Island. In 1996, the
Rhode Island Medical Society's board unanimously voted to
support a policy of syringe decriminalization. This action led to
the Rhode Island Medical Society-sponsored legislation to re-
move legal penalties for syringe possession, which was defeated
by one vote in the state legislature in 1997. In 1998, a compro-
mise bill was passed that reduced the penalty for syringe pos-
session from a felony to a misdemeanor without jail time. This
has lead to a dramatic decrease in arrests for the possession of
syringes. A survey of public places known to be high drug use
areas has shown no increase in discarded syringes in the year
since the law was changed.
However, syringe re-use among injection drug users has
only slightly decreased and still remains higher than most other
states (an average re-use of 14 times). In addition, there has
1 See Peter Lurie & Ernest Drucker, An Opportunity Lost: HIV Infections
Associated with Lack of a National Needle-Exchange Programme in the USA, 349
LANcET 604 (1997) (examining the correlation between the absence of a national
needle-exchange program and preventable HIV infections); see also David Vlahov &
Benjamin Junge, The Role of Needle Exchange Programs in HIV Prevention, 113
PuB. HEALTH REP. 75 (Supp. 11998).
12 See Josiah D. Rich et al., Obstacles to Needle Exchange Participation in
Rhode Island, 21 J. ACQUIR. IMMUNE DE"Ic. SYNDR. 396, 397-99 (1999).
13 See Josiah D. Rich et al., Strategies to Optimize the Impact of Needle Ex-
change Programs, 10 AIDS READER 421 (2000).
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been no change in the street price of syringes since the change
in the law. Anecdotal reports suggest that many injection drug
users are still reluctant to carry their syringes and, despite the
decrease in the penalty for possession, it is still illegal to pur-
chase or sell a syringe without a prescription. Legislation to al-
low the legal purchase and possession of syringes, without a
prescription, has just been passed by the state legislature and
became law in September 2000.
PHYSICIAN SYRINGE PRESCRIPTION
IN RHODE ISLAND
In 1997, Lawrence 0. Gostin, J.D. and Zita Lazzarini, J.D.,
M.P.H., conducted a nationwide review of the state laws regu-
lating syringe possession. 14 Lazzarini pointed out that syringes
could technically be prescribed in Rhode Island, at the discre-
tion of the Director of the State Department of Health.' 5 The
Director of the Rhode Island Department of Health was initially
concerned about the potential for the abuse of syringe prescrip-
tion by unscrupulous physicians.
However, with the support of the Rhode Island Medical So-
ciety, the Rhode Island Pharmacists' Association, the Rhode Is-
land Board of Medical Licensure and Discipline, and the Rhode
Island State Board of Pharmacy, the current Director of the De-
partment of Health, Dr. Patricia Nolan, sent a memo describing
the "Rhode Island Blood Borne Pathogen Harm Reduction Pro-
gram" to all licensed physicians in the state in the spring of
1999.16 This memo states that it is clearly legal to prescribe sy-
ringes with the support of the Department of Health:
The Department of Health is inviting interested physi-
cians to participate in a clinical program to offer sy-
ringes by prescription to injecting drug users in order to
prevent acquiring bloodborne pathogens and/or trans-
mitting them... To participate, a physician will need to
agree to the following:
14 Lawrence 0. Gostin & Zita Lazzarini, Prevention of HIVIAIDS Among
Ijection Drug Users: The Theory and Science of Public Health and Criminal Justice
Approaches to Disease Prevention, 46 EMORY L. 587 (1997).
15 Personal communication by author with Zita Lazzarini, 1997.16 Memorandum from Dr. Patricia Nolan, Director of Health, on the Rhode
Island Bloodbome Harm Reduction Program (Feb. 25, 1999) (on file with author).
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" Agree to document this care in medical record, in-
cluding the assessment of risk of disease transmis-
sion and on-going substance abuse management.
" Make syringe prescription a part of the patient's on-
going medical care;
* Include other harm reduction strategies in the pa-
tient's care;
* Assist patients in disposing of used syringes safely,
and
* Notify the pharmacy at the time of initial prescrip-
tion.
1
It took a considerable amount of time and effort to establish this
degree of local support for physician syringe prescription to
prevent HIV and other diseases.
RHODE ISLAND PHYSICIAN SURVEY
In the spring of 1999, concurrent with the above-noted
memo, we performed a survey of all infectious disease and ad-
diction medicine physicians in Rhode Island. 8 Eighty percent
of the 49 eligible physicians responded. The results are shown
in Table 1. The selected sample of physicians had extensive ex-
perience with injection drug users and patients with HIV or
AIDS. A majority of the physicians were also currently provid-
ing care for injection drug users and patients with HIV infec-
tion.
The results of the survey appear to indicate that most of the
physicians believed that syringe prescription would be a useful
and necessary tool in reducing the transmission of blood-borne
pathogens. Furthermore, almost all of the physicians indicated
that they would prescribe syringes if it were clearly legal. Sev-
eral physicians had been asked by IDU patients for syringes,
and many suspected that diabetic patients were using their sy-
17 id.
18 See Josiah D. Rich et al., Prescribing Syringes to Prevent H!V: A Surey of
Infectiotus Disease and Addiction Medicine Physicians in Rhode Island, 35 SuB-
STANCE UsE & Misusa (forthcoming 2000).
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ringes for purposes other than insulin injection. Despite their
understanding of the issue and willingness, none of the physi-
cians had ever prescribed a syringe for the express intent of
preventing disease among injection drug users.
One of the major obstacles impeding syringe prescription is
the perception surrounding its legality. A number of physicians
completed and returned the survey before receiving the memo
from the Rhode Island Department of Health affirming the le-
gality of providing syringes in the state. However, this does not
account for the incorrect understanding that the majority of the
physicians had about the law. Indeed, many physicians ex-
pressed concern or uncertainty about losing their medical li-
censes and/or getting sued if they prescribed syringes. If syringe
prescription is to be a viable public health strategy, physicians
will need to be educated and reassured about the related laws.
In summary, among a selected group of physicians with
extensive experience treating injection drug users, there is, at
least, a willingness to consider syringe prescription to prevent
HIV transmission. It is unclear how these findings may be gen-
eralized to other physicians in other specialties and/or in other
states.
WHICH INJECTION DRUG USERS SHOULD BE
ELIGIBLE FOR SYRINGE PRESCRIPTION?
In the 1995 report of the National Research Council and the
Institute of Medicine, it was stated that "for injection drug users
who cannot or will not stop injecting drugs, the once-only use
of sterile needles and syringes remains the safest, most effective
approach for limiting HIV transmission." 9 Therefore, any ac-
tive injector could potentially benefit from, and should be eligi-
ble for, the legal provision of syringes by prescription. The pro-
vision of syringes to an active injection drug user to help him or
her move towards the goal of "once-only use of sterile sy-
ringes" is an adequate goal in itself. This is especially true in a
state where syringe access is strictly controlled and IDUs report
high rates of syringe re-use. Equally important is the goal of
19PANEL ON NEEDLE EXCH. & BLEACH DlSTRIB. PROGRAMS, NAT'L RESEARCH
COUNCIL & INST. OF MED., PREVENTING IV TRANSMISSION: THE ROLE OF STERILE
NEEDLES AND BLEACH 2 (Jacques Normand et al. eds., 1995).
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reducing syringe sharing which should dramatically decrease
the transmission of blood-borne diseases.
A major concern about the provision of syringes to injec-
tors is the potential for syringes to act as a "trigger" or a stimu-
lant for an injection drug user to inject. This is more important
when a person is in remission from his or her addiction or trying
to abstain. The best way to minimize the effect of syringes act-
ing as a "trigger" is to educate the client about this possibility.
However, syringes are certainly not the only "trigger" and it is
always possible to get a syringe, but not always possible to find
a sterile one. This is not a reason to not prescribe syringes, but
an issue that should ideally be discussed with each patient, so
that this effect may be minimized.
MEDICAL PROBLEMS OF INJECTION
DRUG USERS
The provision of syringes, although adequate in itself to
justify prescribing, is only a part of the potential benefit. By
definition, the prescription of syringes involves a physician-
patient relationship (or perhaps a health care provider/patient
relationship in the case of physician assistants or nurse practi-
tioners) for a group that is at high risk for many diseases, and
who often do not access health care.
Even prior to the HIV epidemic, injection drug users were
known to be at much higher risk for mortality than the general
population. In New York City between 1965 and 1972, the
death rate of adult heroin users aged 24 to 54 years was esti-
mated to be five times greater than that among age-matched
non-heroin-addicted adults (28.2 per 1000 vs. 5.6 per 1000).20
Violence (including murder and suicide), narcotic overdose, and
infections have accounted for many preventable deaths among
injection drug users. 21 Infections associated with injection drug
use include hepatitis, cellulitis, endocarditis, abscesses, pneu-
monia, sexually transmitted diseases, and tuberculosis. Charac-
teristics of injection drug use which contribute to the transmis-
sion of viral, bacterial, and parasitic microorganisms are un-
20 See Gerald H. Friedland & Peter A. Selwyn, Ifections (Excluding AIDS) in
Injection Drug Users, in HARRISON'S PRINCIPLES OF INTERNAL MEDICINE 831 (An-
thony S. Fauci et al. eds., 14th ed. 1998).21 See Frederick P. Rivara et al., Alcohol and Illicit Drug Abuse and the Risk
of Violent Death in the Home, 278 JAMA 569,573-74 (1997).
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sterile injection technique, contaminated water used to dissolve
drugs or rinse equipment afterward, and shared injection
equipment.
22
In our experience, the primary causes of death for HIV in-
fected addicts with CD4 counts above 200 (generally prior to
the development of AIDS) are related to injection drug use. In a
recent study of HIV-positive women who died at our center, 18
out of 100 died before developing AIDS.23 Seventeen of the 18
were injection drug users. Ten died of an overdose, one of en-
docarditis, one of alcohol-related cirrhosis, one of alcohol-
related pancreatitis, and one of homicide related to narcotics.
It is estimated that 29% of hepatitis-related deaths are IDU-
associated. There were more than two million drug-related cases
of hepatitis in 1995. Estimates range between 70% to 90% of
injection drug users that have positive tests for hepatitis C. Up
to 85% of people with hepatitis C will develop chronic hepati-
tis. Liver failure due to chronic hepatitis C is the leading cause
of liver transplants in the United States.
24
Access to medical care can help to identify, treat, and pre-
vent many of these diseases. This includes sexually transmitted
disease screening and treatment, HIV and hepatitis B and C
screening, hepatitis B vaccination, tuberculosis screening, pap
smear testing, and general primary care, ideally with "one-stop-
shopping."
BARRIERS TO MEDICAL CARE AMONG
INJECTION DRUG USERS
Injection drug users also have substantial barriers to re-
ceiving medical care. The subculture created to sustain the ille-
gal activities of injection drug users also makes them a "hidden"
population with limited access to primary health care. Care is
hindered by availability as well as by the fear of moral judg-
22 See Friedland & Selwyn, supra note 20, at 831-35.
2" See E. Mylonakis et al., Substance Abuse is Responsible for Most Pre-AIDS
Deaths Among Women with HIV Infection in Providence, Rhode Island, USA, 12
AIDS 958, 959 (1998).
24 See J. Michael McGinnis & William H. Foege, Mortality and Morbidity
Attributable to Use of Addictive Substances in the United States, 111 PROC. ASS'N
AM. PHYSICIANS 109, 114-15 (1999); see also Loma E. Thorpe et al., Hepatitis C
Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities Among




ment or even legal reprisal when injection drug users access
traditional health care services. There exists a tremendous
amount of fear and mistrust about the medical establishment, in
part because of the response injection drug users get when their
injection practices are revealed. In addition, injection drug users
(as is true of other chemically dependent individuals) often lead
unstable, chaotic lives which make it less likely that they will
have the perseverance to make and keep an appointment for a
medical visit several weeks in advance. This tendency not to
keep scheduled appointments is one reason that injection drug
users may be viewed as undesirable patients in the medical pro-
vider community. They may be less likely to comply with pre-
scribed treatments, keep appointments, and tolerate delays in
obtaining an appointment for treatment.2 5 These characteristics
do not blend well with high threshold facilities nor with practi-
tioners who are not accustomed to an addicted patient popula-
tion.
Economic and social barriers also prevent injection drug
users from accessing existing services. These barriers include a
higher incidence of unemployment, poverty, and homelessness
with a concomitant lack of medical insurance and transporta-
tion. There are a myriad of systematic and individual barriers to
medical care that result in low levels of health care for a popu-
lation at high risk for disease. Providing low threshold access to
primary care is possible in a variety of ways-these include
25 See David Bangsberg et al., Protease Inhibitors in the Homeless, 278
JAMA 63, 63 (1997) (stating that problems of treatment adherence in the homeless
population are demonstrated in tuberculosis studies and therefore raise similar con-
cers for drug users and antiretroviral therapy); see also David D. Celentano et al.,
Self-Reported Antiretroviral Therapy in Injection Drug Users, 280 JAMA 544, 545
(1998) (commenting that unstable living conditions of intravenous drug users affect
antiretroviral therapies prescribed by healthcare providers); Patrick G. O'Connor et
al., Medical Care for Injection-Drug Users with Human Immunodeficiency Virus
Infection, 331 NEw ENG. J. MED. 450, 455 (1994) (arguing that the lack of primary
care among HV-infected injection drug users causes delays in treatment and pro-
longed hospitalization); Mark Senak, Predicting Antiviral Compliance: Physicians'
Responsibilities vs. Patients' Rights, J. INT'L ASS'N PHYSICIANS IN AIDS CARS, June
1997, at45 (noting that an holistic approach may be needed to attain compliance with
drug regimens); Deborah Sontag & Lynda Richardson, Doctors Withhold H.LV. Pill
Regimen from Some: Failure to Follow Rigid Schedule Could Hurt Others, They
Fear, N.Y. TMEs, March 2, 1997, at Al; Steffanie A. Strathdee et al., Barriers to
Use of Free Antiretroviral Therapy in Injection Drug Users, 280 JAMA 547 (1998).
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26
storefront clinics in low-income neighborhoods, mobile health
clinics (vans), clinics associated with drug treatment facilities,27
and clinics created in conjunction with NEPs and other commu-
nity services. Providing services in a manner that is cognizant
and respectful of patients, such as drop-in hours, appointment
flexibility, and nonjudgmental interactions helps overcome bar-
riers to access. Language competency, provision of child care,
provision of bus or cab tokens, and diversity of staff are all ex-
amples of gender, racial, and cultural sensitivity which expand
access to care for marginalized populations. Finally, since a
major obstacle is the lack of insurance, the availability of free
or sliding scale services is essential to providing care to injec-
tion drug users as well as other substance abusers.
BARRIERS TO SUBSTANCE ABUSE TREATMENT
AMONG INJECTION DRUG USERS
There exist substantial barriers to substance abuse treat-
ment as well. Though substance abuse treatment has repeatedly
been demonstrated to be effective in reducing drug use and its
harmful sequelae, most injection drug users are not engaged in
treatment. It is estimated that only one of six injection drug us-
ers is in treatment at any given time.28 Given the chronic, re-
lapsing nature of addiction, it is common for injection drug us-
ers to enter treatment in a "revolving door" fashion. They tend
to have an unstable and sporadic involvement in treatment over
time.29 In 1998, 40% of the 2,425 in-patient admissions for
medical detoxification services in Rhode Island left prior to
26 See Nathaniel Gunn et al., Primary Care as Harm Reduction for Injection
Drug Users, 280 JAMA 1191 (1998) (noting that a primary care clinic targeting the
IDU population benefitted both drug users and student physician knowledge).
7 See Patrick G. O'Connor et al., Human Immunodefiency Virus Infection in
Iutravenous Drug Users: A Model for Primary Care, 93 AM. I. MED. 382 (1992)
(providing primary care in conjunction with treatment facilitated compliance among
HIV-infected intravenous drug users).
28 See Robert E. Booth et al., Facilitating Treatment Entry Among Out-of-
Treatment Injection Drug Users, 113 PUB. HEALTH REP. 116, 118 (Supp. 1 1998)
(reporting on the effectiveness of intervention strategies targeting out-of-treatment
IDUs).
29 See David S. Metzger et al., Drug Abuse Treatment as AIDS Prevention,
113 PUB. HEALTH REP. 97,98 (Supp. 11998).
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program completion.30 These gaps in treatment place individu-
als at renewed and increased risk for HIV infection.
31
Barriers to treatment are described in a National Institute
on Drug Abuse (NIDA) funded ethnographic study of 70 out-of-
treatment heroin addicts. 32 These barriers included high-
threshold programs such as those with long waiting lists and
few available subsidized treatment slots. Many participants
lived on public assistance and supplemented their incomes with
illicit activities. Payment of private fees for methadone mainte-
nance was often out of the question. Without relying on in-
volvement in illegal activities, they are unable to pay private
fees since welfare income barely finances basic needs. Treat-
ment intake procedures were time-consuming, complicated, and
demanding. Examples of wait-listing included daily call-backs
to prove their motivation or being put on a wait-list to call back
in a month or several months. This process was made all the
more difficult as many participants were without phones or
permanent residences.
Certainly not all barriers to substance abuse are institu-
tional. Both the physical and psychological addictions of heroin
or cocaine are powerful motivators for continuing to inject.
Drug use in general is often a coping mechanism for dealing
with past or current traumas. Addressing those traumas without
the benefit of drugs may be overwhelming for many individuals.
Additionally, "getting clean" may entail giving up social net-
works that have been an important, if not healthy, part of the
injector's life. There is no doubt that many substance users per-
ceive benefits to continued injection drug use and the act of en-
tering treatment to be fraught with indecision. It is precisely this
indecision which can be influenced by a trusting physician-
patient relationship.
Physician syringe prescription can act as a tool for outreach
to a high risk, and often out-of-treatment population of drug us-
ers. It is a way to tap into drug-using networks and bring those
3) See Rhode Island Dep't of Health, Health by Numbers (Apr. 1998).
31 See Diana M. Hartel & Ellie E. Schoenbaum, Methadone Treatment Pro-
tects Against HIV Infection: Two Decades of Experience in the Bronx, New York
City, 113 PuB. HEALTH REP. 107, 112 (Supp. I 1998) (finding that longer time in
treatment is associated with a lower probability of HIV infection).
32 See Lynn D. Wenger & Marsha Rosenbaum, Drug Treatment on Demand-
Not, 26 J. PSYCHOACT7VE DRUGS 1, 2-4 (1994) (analyzing the effect of the lack of on-
demand drug treatment).
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populations into a care system. Moreover, syringe prescription
is appropriate at whatever stage an injector is in-initial use,
prolonged use, relapse, and possibly even recovery. At each
step, interest in and access to substance abuse treatment should
be addressed.
PHYSICIAN SYRINGE PRESCRIPTION STUDY
In order to evaluate the feasibility, acceptability, and out-
come of physician syringe prescription, we have begun a pilot
program in Providence, Rhode Island. This program, and its
evaluation, began with funding from the Open Society Institute
and the American Foundation for AIDS Research. Additional
funding from the Center for Substance Abuse Treatment
(CSAT) to evaluate the physician-patient motivational inter-
vention has been recently awarded. The program is situated at
two locations, an academic teaching hospital and an inner city
community clinic. We began enrolling clients in the
spring/summer of 1999. We have an active recruitment pro-
gram, which includes flyers, word-of-mouth, and business
cards, with a toll-free telephone number. We have approached
injection drug users in medical care, especially HIV infected
individuals. We have also worked closely with prison discharge
planners, drug treatment, and detoxification programs, including
methadone maintenance programs and street outreach in high
drug use areas.
Participants undergo a five-minute telephone screening to
determine eligibility, and if they qualify, they are scheduled for
an evaluation that involves a 30-40 minute administered ques-
tionnaire. The medical visits are then arranged, and often occur
on the same day as the baseline evaluation. Participants are re-
imbursed for the baseline evaluation ($10), a three-month
evaluation ($20), a six-month evaluation ($25), and a 12-month
evaluation ($30). Medical visits are scheduled as often as
needed. The staff currently includes four physicians, one sub-
stance abuse referral specialist, one nurse, two interviewers, and
one administrator. To date (December 15, 2000), we have had
413 phone screens, of whom 338 have been successfully en-
rolled and 295 have been seen by a physician.
Syringes are prescribed, usually 100 at a time, and addi-
tional syringes are prescribed by the physician as often as nec-
essary to prevent the reuse and sharing of syringes. Syringes are
provided for free to the clients with private funding. Patients are
2001]
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instructed on safe injection and safe disposal and encouraged to
either return syringes or dispose of them appropriately, in ac-
cordance with the Rhode Island Department of Health recom-
mendations. Biohazard containers are provided for free. Phar-
macists are notified at the time of the first prescription and only
two designated pharmacies have been utilized, thus far. Other
clients have been the most common source of referrals.
PRELIMINARY IMPRESSIONS AND ISSUES
When the physician-patient relationship begins with the ac-
knowledgement of injecting behaviors, there is an enhanced
element of trust and confidence. Anecdotally, patients seem to
be comfortable in accepting help and advice, and being more
open and honest. This facilitates the provision of medical care
and increases the possibility of participating in other services,
including psychiatric care and substance abuse treatment serv-
ices.
(1) Initial recruitment was slower than anticipated. We
thought that with a street price of syringes at five dollars, some
individuals might participate in the study in order to sell sy-
ringes. This does not seem to be happening to any great extent.
Clients are not selling syringes at a high rate and they are not
refilling syringe prescriptions more than they seem to use them.
They have anecdotally reported providing syringes to others in
need. Almost all have reported decreased syringe sharing or sy-
ringe reuse. Two individuals, after an initial interview with a
physician, when offered the option, chose to go immediately
into drug treatment. After this decision was made, they both
were again offered free sterile syringes, in case they needed
them. They both decided not to receive the syringes. Several
others have specifically requested less than a hundred syringes.
More recently enrollment has dramatically increased through
word-of-mouth.
(2) The participants seem to be open and honest about their
drug use and understand that physicians are trying to help them
in a non-judgmental way, and they are quite appreciative of the
physician's efforts. Participants are extremely willing to par-
ticipate in healthcare including hepatitis B vaccination, HIV,
hepatitis C, sexually transmitted disease, and tuberculosis test-
ing and follow-up.
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(3) The physician-patient interaction based on the acknow-
ledgement of injecting behaviors seems to open the door for
discussing a whole host of injecting related activities including
prostitution, participation in the underground economy, vio-
lence, and abuse. As a physician, one has an opportunity to see
how chaotic the lives of some of these individuals are, and how
many of them are at extremely high risk for transmission of in-
fectious diseases, as well as other medical illnesses, psychiatric
and psychological disorders, and violence.
(4) Most participants generally report appropriate disposal
of syringes. However, despite the provision of free biohazard
containers, and encouragement to return used syringes to the
clinic, few do so. Most are concerned that contaminated sy-
ringes will be used by others and therefore report breaking the
tips off prior to disposing them in puncture-proof containers.
However, there is a reluctance among many to carry a large
number of syringes back to the program. As nearly half are
homeless, many prefer not to even have the biohazard contain-
ers.
(5) Some clients report being reluctant to use a single sy-
ringe only once ("it seems like a waste"), which is not surpris-
ing given that once-only use is very different from what most
drug injectors in Rhode Island are used to. It may take time and
a consistent supply of syringes to change some injecting prac-
tices, such as syringe reuse.
CONSIDERATIONS FOR OTHERS WHO WOULD
CONSIDER PRESCRIBING SYRINGES TO
INJECTION DRUG USERS IN OTHER LOCATIONS
(1) Know the law. It is important to clarify, or at least
know, the local legal status of prescribing syringes. As we were
the first to prescribe on a large scale, we believed that it was
important to be certain that what we were doing was legal.
(2) Document in the medical record the need for and ra-
tionale for prescribing syringes, and that attempts at alternative
options were tried (such as referral to substance abuse treat-
ment).
(3) Seek local support. We received considerable local sup-
port. Again, being that we were the first, this level of support




(4) Evaluate outcomes if possible. As with any new and
unproven strategy, it is helpful to have data to evaluate this
strategy and convince others to support it.
(5) It is critically important to create linkages to other pro-
grams that can assist this population, especially substance abuse
treatment programs.
CONCLUSIONS
Physician syringe prescription for injection drug users is
feasible. There have been no major problems, and the physi-
cian-patient and the pharmacist-patient interactions have gone
well. It is too early to tell the long-term effects of this interven-
tion on ongoing risk behavior, drug use, or participation in
medical, social, and substance abuse treatment services, but
these are current areas of study. Physician syringe prescription
can be extremely rewarding from the physician's standpoint,
and other physicians may be encouraged to begin prescribing
syringes to injection drug users. In addition to the benefit of
providing legal access to sterile syringes for injection drug us-
ers, syringe prescription creates an opportunity to provide
medical, social, psychiatric, and substance abuse treatment to a
population in desperate need.
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Table 1: Physicians' Opinions
Statement Agree Disagree Unsure
I would prescribe syringes to
prevent disease in an IDU if it 72% 5% 23%
were clearly legal to do so.
It is currently legal to prescribe
syringes in Rhode Island to 26% 56% 18%
prevent disease in IDUs.
There is a legitimate medical
reason for injection drug users 95% 0% 5%
to obtain sterile syringes.
It is not the role of physicians
to provide IDU patients with 8% 79% 13%
syringes to inject illegal drugs.
I am opposed to prescribing
syringes to injection drug users 3% 95% 3%
on moral/ethical grounds.
Syringe prescription should
involve referrals for addiction 87% 8% 5%
treatment.
Syringe prescriptions should be
strictly monitored with a heavy 69% 18% 13%
emphasis on entering drug
treatment.
My medical license might be in
jeopardy if I prescribe syringes 28% 38% 31%
to IDUs.
I might get sued if I prescribe
syringes to IDUs. 28% 33% 36%
Injection drug users would
make my office less comfort- 26% 59% 8%
able for other patients.
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